Menevit Study: Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00100269

Recruitment Status : Completed

First Posted : December 28, 2004

Last Update Posted : May 3, 2006

Sponsor:

Information provided by:

Repromed

Study Description

Brief Summary:

Oxidative stress related damage to sperm is believed to be a major cause of male infertility. The object of the Menevit study is to investigate the role of a novel anti-oxidant preparation (Menevit) on sperm function, embryo quality and pregnancy rates in an in vitro fertilization (IVF) setting.

Condition or disease	Intervention/treatment	Phase
Infertility, Male Oxidative Stress	Drug: Menevit anti-oxidant	Phase 3

Detailed Description:

Men will be screened for oxidative stress (free radical) related damage to their sperm. This will include screening for lipid peroxidation of sperm using the LPO-586 assay, HOST test and for sperm DNA fragmentation using the Tunel technique. Those men found to have free radical related damage will be enrolled in a randomized control trial in which they will receive either the Menevit anti-oxidant or placebo (in a 2:1 randomization ratio respectively). The Menevit anti-oxidant is a capsule containing several different anti-oxidants, taken orally once per day. The placebo is identical in appearance and taste. After 3 months of Menevit/placebo the female partners of these men will undergo an IVF oocyte retrieval operation and embryo transfer. Pregnancy rates and embryo quality will be compared between groups. Changes in semen characteristics (count, motility, morphology, membrane integrity) and lipid peroxidation (LPO-586) plus sperm DNA fragmentation (Tunel assay) will be assessed at trial entry, 6 weeks and 3 months. Comparisons between the patients embryo quality in the IVF cycle immediately before and during the Menevit trial will also be compared when possible

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	60 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Randomized Control Trial of the Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility
Study Start Date :	December 2004
Study Completion Date :	March 2006

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: CATSPER1-related nonsyndromic male infertility Y chromosome infertility Sensorineural deafness and male infertility

MedlinePlus related topics: Antioxidants Infertility Male Infertility

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Embryo quality (morphology score, progression to blastocyst rates, number of embryos available for freezing/transfer per cycle)
Embryo quality is a good measure of pregnancy potential and is also an indicator of sperm DNA integrity, making it the ideal primary endpoint.

Secondary Outcome Measures :

sperm DNA fragmentation
sperm count
sperm motility (total motile sperm per ejaculate)
sperm morphology
sperm membrane integrity (as assessed by hypo-osmolar swelling test)
levels of sperm lipid peroxidation (LPO-586 assay)
retrospective comparison of embryo quality between the Menevit IVF cycle and the preceding non-Menevit IVF cycle.
miscarriage rate (clinical and biochemical)
clinical pregnancy rates (number of fetal hearts seen on first trimester scan)
adverse side effects

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Evidence of oxidative stress to sperm on LPO-586 assay or poor HOST result or clinical evidence for oxidative stress (heavy smoker, varicocele, poor motility in the abscence of anti-sperm antibodies etc)
Evidence of significant sperm DNA damage (25% or more DNA fragmentation as assessed by Tunel assay).
Female partner willing to undergo IVF treatment within 3 months of starting Menevit trial

Exclusion Criteria:

Female partner 40 years of age or older at trial entry.
Significantly reduced ovarian reserve in female partner (day 3-5 FSH > 10 iu/L if no prior IVF cycle or less than 5 oocytes on a prior IVF cycle.
Sperm count below 0.5 million per ml (impossible to conduct all sperm function assays

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00100269

Locations


Australia, South Australia
Repromed
Adelaide, South Australia, Australia, 5065

Sponsors and Collaborators

Repromed

Investigators


Principal Investigator:	Kelton P Tremellen, MB BS (Hons) PhD	Repromed, University of Adelaide

More Information

Publications:

Aitken RJ, Baker MA. Oxidative stress and male reproductive biology. Reprod Fertil Dev. 2004;16(5):581-8. Review.

Aitken RJ, Gordon E, Harkiss D, Twigg JP, Milne P, Jennings Z, Irvine DS. Relative impact of oxidative stress on the functional competence and genomic integrity of human spermatozoa. Biol Reprod. 1998 Nov;59(5):1037-46.

Benchaib M, Braun V, Lornage J, Hadj S, Salle B, Lejeune H, Guérin JF. Sperm DNA fragmentation decreases the pregnancy rate in an assisted reproductive technique. Hum Reprod. 2003 May;18(5):1023-8.

Henkel R, Hajimohammad M, Stalf T, Hoogendijk C, Mehnert C, Menkveld R, Gips H, Schill WB, Kruger TF. Influence of deoxyribonucleic acid damage on fertilization and pregnancy. Fertil Steril. 2004 Apr;81(4):965-72.

Carrell DT, Liu L, Peterson CM, Jones KP, Hatasaka HH, Erickson L, Campbell B. Sperm DNA fragmentation is increased in couples with unexplained recurrent pregnancy loss. Arch Androl. 2003 Jan-Feb;49(1):49-55.

Agarwal A, Nallella KP, Allamaneni SS, Said TM. Role of antioxidants in treatment of male infertility: an overview of the literature. Reprod Biomed Online. 2004 Jun;8(6):616-27. Review.

Gomez E, Irvine DS, Aitken RJ. Evaluation of a spectrophotometric assay for the measurement of malondialdehyde and 4-hydroxyalkenals in human spermatozoa: relationships with semen quality and sperm function. Int J Androl. 1998 Apr;21(2):81-94.


ClinicalTrials.gov Identifier:	NCT00100269 History of Changes
Other Study ID Numbers:	RCHDW002
First Posted:	December 28, 2004 Key Record Dates
Last Update Posted:	May 3, 2006
Last Verified:	June 2005

Keywords provided by Repromed:


Male infertility sperm pregnancy IVF (in vitro fertilisation)	oxidative stress free radicals DNA damage

Additional relevant MeSH terms:


Infertility Infertility, Male Genital Diseases, Male Genital Diseases, Female	Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs

To Top